文献速递儿童心血管与肾脏儿童感染

幼儿ABO不相容与相容心脏移植的临床结局:多中心队列研究

Clinical outcomes of children receiving ABO-incompatible versus ABO-compatible heart transplantation: a multicentre cohort study.
PubMed 文献 · Lancet Child Adolesc Health · 2021-03-18

该多中心前瞻性队列研究基于儿科心脏移植学会注册数据,比较2岁前接受ABO不相容与相容心脏移植儿童的长期结局。匹配后两组移植物生存、冠状动脉移植物血管病和恶性肿瘤发生率相似,ABO不相容组严重感染、细菌感染及多糖荚膜细菌感染更少。提示ABO不相容移植在2岁以下儿童中是临床安全的方法。

要点

  • 2岁前ABO不相容心脏移植的移植物生存与ABO相容移植相似。
  • 匹配后两组排斥反应、冠状动脉移植物血管病和恶性肿瘤无显著差异。
  • ABO不相容移植与更少的细菌感染(尤其荚膜细菌)相关。

核心结论

  • 2岁以下儿童ABO不相容心脏移植临床安全,生存率及排斥、冠状动脉移植物血管病、恶性肿瘤发生率与ABO相容移植相似。
  • ABO不相容移植与更少的细菌感染(尤其荚膜细菌)相关,提示获得性免疫改变可能有益。

研究设计与样本

  • 多中心前瞻性队列研究,分析儿科心脏移植学会注册库1999年1月1日至2018年6月30日数据。
  • ABO不相容组364例,ABO相容组1842例;采用倾向评分匹配,每个ABO不相容受者匹配2个ABO相容受者。

主要发现

  • ABO不相容组更年轻,先天性心脏病、呼吸机和机械循环支持比例更高。
  • 匹配后两组仅血型分布和抗胸腺细胞球蛋白多克隆诱导治疗使用存在差异。

临床怎么用

  • 对于2岁以下需要心脏移植的儿童,ABO不相容移植可作为扩大供体来源的安全选择。
  • ABO不相容移植后严重细菌感染风险可能较低,但仍需常规感染监测。

局限性

  • 研究为注册库队列研究,可能存在未测量的混杂因素。
  • 匹配后血型分布和诱导治疗仍存在差异,可能影响结果解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: ABO-incompatible heart transplantation increases donor availability in young children and is evolving into standard of care in children younger than 2 years. Previous smaller studies suggest similar outcomes to ABO-compatible heart transplantation, but persisting alterations of the immune system in ABO-incompatible recipients might increase the risk of some infections or benefit the graft owing to reduced HLA reactivity. We aimed to assess long-term outcomes in young children after they received ABO-incompatible or ABO-compatible heart transplantation. METHODS: In this multicentre, prospective cohort study, we analysed data from the Pediatric Heart Transplant Society registry to compare children who received ABO-incompatible or ABO-compatible heart transplantation before age 2 years between Jan 1, 1999, and June 30, 2018. Given significantly different clinical demographics between the two groups, we also matched each ABO-incompatible recipient to two ABO-compatible recipients using propensity score matching. We assessed patient and graft survival, coronary allograft vasculopathy, malignancy, acute rejection (any episode resulting in augmentation of immunosuppression), and infections (requiring intravenous antibiotic or antiviral therapy or life-threatening infections treated with oral therapy). FINDINGS: We included 2206 children who received a heart transplant before age 2 years, with 11 332·6 patient-years of cumulative observation time. Children who received an ABO-incompatible transplant (n=364) were younger and a larger proportion had congenital heart disease and ventilator and mechanical circulatory support than the ABO-compatible recipients (n=1842). After matching, only differences in blood group (more O in ABO-incompatible and more AB in ABO-compatible groups) and use of polyclonal induction therapy with anti-thymocyte globulins persisted. The two matched groups had similar post-transplantation graft survival (p=0·74), freedom from coronary allograft vasculopathy (p=0·75), and malignancy (p=0·51). ABO-incompatible recipients showed longer freedom from rejection (p=0·0021) in the overall cohort, but not after matching (p=0·48). Severe infections (p=0·0007), bacterial infections (p=0·0005), and infections with polysaccharide encapsulated bacteria (p=0·0005) that share immunological properties with blood group antigens occurred less frequently after ABO-incompatible heart transplantation. INTERPRETATION: ABO-incompatible heart transplantation for children younger than 2 years is a clinically safe approach, with similar survival and incidences of rejection, coronary allograft vasculopathy, and malignancy to ABO-compatible recipients, despite higher-risk pre-transplant profiles. ABO-incompatible transplantation was associated with less bacterial infection, particularly encapsulated bacteria, suggesting that the acquired immunological changes accompanying ABO tolerance might benefit rather than jeopardise transplanted children. FUNDING: Pediatric Heart Transplant Society.

来源:Lancet Child Adolesc Health,查看原文。版权归原作者所有。

引用

  1. Urschel S, Ballweg JA, Cantor RS, et al. Clinical outcomes of children receiving ABO-incompatible versus ABO-compatible heart transplantation: a multicentre cohort study. Lancet Child Adolesc Health. 2021. PMID: 33743201. doi:10.1016/S2352-4642(21)00023-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。